The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs
- 14 November 2004
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 65 (1) , 35-43
- https://doi.org/10.1016/j.antiviral.2004.09.004
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapyExpert Review of Anti-infective Therapy, 2004
- The treatment of cytomegalovirus infectionJournal of Antimicrobial Chemotherapy, 2002
- Susceptibilities of Human Cytomegalovirus Clinical Isolates to BAY38-4766, BAY43-9695, and GanciclovirAntimicrobial Agents and Chemotherapy, 2001
- A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene ProductsJournal of Virology, 2001
- Molecular Cloning of the Guinea Pig Cytomegalovirus (GPCMV) Genome as an Infectious Bacterial Artificial Chromosome (BAC) in Escherichia coliMolecular Genetics and Metabolism, 2001
- Combined treatment with 2′-nor-cGMP and ganciclovir against cytomegalovirus infection in a guinea pig modelAntiviral Research, 1992
- Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigsAntiviral Research, 1990
- Cytomegalovirus infection in immunocompromised guinea pigs: A model for testing antiviral agents in vivoAntiviral Research, 1989
- Evaluation of new antiviral agents: I. In vitro perspectivesAntiviral Research, 1989
- Cytomegaloviral Infections in the Guinea Pig: Experimental Models for Human DiseaseClinical Infectious Diseases, 1983